What is Switch Therapeutics?
Switch Therapeutics is focused on pioneering genetic medicines that are gated by specific biomarkers, aiming to revolutionize how diseases are treated. The company's innovative approach targets the underlying mechanisms of disease, promising more precise and effective therapeutic interventions. This strategic direction positions Switch Therapeutics at the forefront of biotechnology innovation, leveraging cutting-edge science to address unmet medical needs.
How much funding has Switch Therapeutics raised?
Switch Therapeutics has raised a total of $52M across 1 funding round:
Series A
$52M
Series A (2023): $52M with participation from Upfront Ventures, BOLD Capital Partners, Eli Lilly, Insight Partners, and UCB Ventures
Key Investors in Switch Therapeutics
Upfront Ventures
Upfront Ventures is a venture capital firm based in Los Angeles, specializing in technology businesses with a focus on digital media, SaaS, consumer internet, and retail innovation, supporting startups seeking capital for growth.
BOLD Capital Partners
BOLD Capital Partners is a venture capital firm that invests in entrepreneurs and technologies aiming to transform the world, focusing on emerging science and technologies that can disrupt large markets and address significant global challenges.
Eli Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines, with a focus on diabetes, oncology, immunology, and neuroscience.
What's next for Switch Therapeutics?
With a substantial enterprise-level funding context, Switch Therapeutics is poised for significant scaling and further development of its therapeutic pipeline. The recent major strategic investment suggests strong confidence from its backers in the company's technology and market potential. This capital infusion will likely accelerate research and development efforts, clinical trial progression, and the expansion of its operational capabilities, moving Switch Therapeutics closer to bringing its transformative treatments to patients.
See full Switch Therapeutics company page
